Morphine injection near the stellate ganglion to reduce heart damage after a heart attack

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with acute ST-elevation myocardial infarction (STEMI) who are planned for primary percutaneous coronary intervention (PCI) will be randomized to receive a single ultrasound-guided injection of morphine or saline around the left stellate ganglion before coronary recanalization. Investigators will compare infarct size about 7 days after the procedure (or at discharge if sooner) and will monitor patients for safety and procedure-related complications. Key exclusions include severe post-MI complications, prior MI or cardiomyopathy, coagulation disorders, opioid allergy or dependence, pregnancy, severe organ dysfunction, and inability to consent. The trial is conducted at participating hospitals in Hefei and Changsha, China, under institutional oversight.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged ≥18 years, Male or Female.
2. Acute ST-segment elevation myocardial infarction (STEMI) patients planned for percutaneous coronary intervention (PCI). Acute STEMI is defined as: electrocardiogram shows ST-segment elevation ≥0.2 mV in two or more adjacent leads, or new left bundle branch block (LBBW).
3. Within 24 hours of the onset of infarct-related chest pain.
4. Obtaining informed consent from the patient and their family.

Exclusion Criteria:

1. Patients with severe complications of myocardial infarction, such as uncontrollable acute left heart failure and pulmonary edema, severe cardiogenic shock after cardiopulmonary resuscitation, severe mechanical complications including ventricular septal defect, papillary muscle rupture, and rupture of the left ventricular free wall;
2. Patients with old myocardial infarction, or cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs;
3. Patients with coagulation disorders due to systemic diseases and those who are currently using anticoagulants and are not suitable for injection;
4. Patients allergic to opioids or with a history of opioid addiction and those participating in other clinical studies;
5. Pregnant or breastfeeding women;
6. Patients with severe organ dysfunction or failure, such as liver failure, renal failure, and respiratory failure;
7. Patients with severe infections;
8. Patients with severe mental illness that cannot cooperate and those taking antipsychotic drugs;
9. Other patients considered unsuitable for this study by the researchers.

Where it's running

• The First Affiliated Hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting
• The Second Affiliated Hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting
• The Second Xiangya Hospital of Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Shiyun Jin, M.D., PhD.
• Email: xingzheruyun@126.com
• Phone: +86 055163869480

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

  See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.

  Recruiting at 2 sites Phase 4 National Institute of Cardiovascular Diseases, Pakistan · Karachi, Sindh and 1 other locations · NCT07536802

• Subclinical depression in people after a first heart attack (SUBDIMA25)

  This project will test how common mild depressive symptoms are in adults hospitalized for a first heart attack and whether those symptoms relate to biomarkers, heart function, and recovery over the next year.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italia · NCT07492537

• Long-term follow-up after Hearticellgram-AMI treatment

  We will follow people who got one dose of Hearticellgram-AMI after a heart attack for up to 60 months to see if the treatment stays safe.

  Recruiting Pharmicell Co., Ltd. · Seoul, Gangnam · NCT07400458

• Long-term remote ischemic preconditioning after a heart attack

  This trial will test whether daily brief arm blood‑flow restriction after a recent heart attack can lower the chance of major heart and brain events over the following year for people treated for acute myocardial infarction.

  Recruiting Henan Institute of Cardiovascular Epidemiology · Zhengzhou, Henan · NCT07181356

• Using wearable devices to monitor heart attack patients

  This study tests whether wearable devices can help monitor heart attack patients in the hospital to improve their care and predict their recovery.

  Recruiting RenJi Hospital · Shanghai · NCT06995495

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.